Hemispherx Lied About Immune Disorder Drug, Investor Says

Law360, Los Angeles (January 16, 2013, 6:52 PM EST) -- A Hemispherx Biopharma Inc. shareholder hit the drugmaker and its executives with a derivative suit in Pennsylvania federal court Tuesday, accusing the company of lying about the safety and efficacy of its chronic fatigue syndrome drug, which annihilated its stock price after the medication’s study results were questioned.

Hemispherx investor Mark Zicherman filed the lawsuit claiming six Hemispherx directors knowingly breached their fiduciary duties to shareholders by announcing the company had obtained positive results in clinical trials on Ampligen, a chronic fatigue syndrome drug it is...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

ZICHERMAN v. CARTER et al


Case Number

2:13-cv-00243

Court

Pennsylvania Eastern

Nature of Suit

Contract: Stockholders Suits

Judge

WENDY BEETLESTONE

Date Filed

January 15, 2013

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.